AUTHOR=Fernandes Messias Márcia Cristina , Mecatti Giovana Colozza , Figueiredo Angolini Célio Fernando , Eberlin Marcos Nogueira , Credidio Laura , Real Martinez Carlos Augusto , Rodrigues Coy Cláudio Saddy , de Oliveira Carvalho Patrícia TITLE=Plasma Lipidomic Signature of Rectal Adenocarcinoma Reveals Potential Biomarkers JOURNAL=Frontiers in Oncology VOLUME=7 YEAR=2018 URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2017.00325 DOI=10.3389/fonc.2017.00325 ISSN=2234-943X ABSTRACT=Background

Rectal adenocarcinoma (RAC) is a common malignant tumor of the digestive tract and survival is highly dependent upon stage of disease at diagnosis. Lipidomic strategy can be used to identify potential biomarkers for establishing early diagnosis or therapeutic programs for RAC.

Objective

To evaluate the lipoperoxidation biomarkers and lipidomic signature in the plasma of patients with RAC (n = 23) and healthy controls (n = 18).

Methods

Lipoperoxidation was evaluated based on malondialdehyde (MDA) and F2-isoprostane levels and the lipidomic profile obtained by gas chromatography and high resolution mass spectrometry (ESI-q-TOF) associated with a multivariate statistical technique.

Results

The most abundant ions identified in the RAC patients were those of protonated phosphatidylcholine and phosphatidylethanolamine. It was found that a lisophosphatidylcholine (LPC) plasmalogen containing palmitoleic acid [LPC (P-16:1)], with highest variable importance projection score, showed a tendency to be lower in the cancer patients. A reduction of n − 3 polyunsaturated fatty acids was observed in the plasma of these patients. MDA levels were higher in patients with advanced cancer (stages III/IV) than in the early stages groups and the healthy group (p < 0.05). No differences in F2-isoprostane levels were observed among these groups.

Conclusion

This study shows that the reduction in plasma levels of LPC plasmalogens associated with an increase in MDA levels may indicate increased oxidative stress in these patients and identify the metabolite LPC (P-16:1) as a putatively novel lipid signature for RAC.